Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

    --  Four expert-led educational events with Allergan Medical Institute
        (AMI), Science of Aging(TM) and Allergan Aesthetics (AA) Global Medical
        Affairs
    --  AMI symposia will focus on a new Allergan Aesthetics (AA) Signature
        Program and celebrate 10 years of MD Codes(TM), with live injection
        sessions and fireside chat with world-renowned plastic surgeon Dr.
        Maurício de Maio
    --  Eleven E-Poster data presentations and Meet the Expert sessions with
        Global experts live from the Allergan Aesthetics booth

NORTH CHICAGO, Ill., March 24, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment outcomes with new AA Signature program at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Thursday, March 27- Saturday, March 29, 2025.

Activities will center around the new AA Signature program - an innovative approach to treatment planning harnessing the power of Allergan Aesthetics advanced portfolio to address different patient needs, including Lift, Definition and Skin Quality, and a celebration of 10 years of MD Codes(TM), which has revolutionized aesthetic medicine with innovative methodology to guide injectors' technique and elevate patient outcomes.

AMI Symposia
Meetings will take place as follows:

    --  Design your patients' look with the NEW Signature approach by Allergan
        Aesthetics. 11.15 AM - 1:15 PM on Thursday, March 27 in the Salle des
        Princes, Grimaldi Forum.
    --  MD Codes(TM) and Allergan Aesthetics: a decade of excellence and a
        signature of success for the future. 9:45 AM- 12:45 PM on Friday, March
        28 in the Salle des Princes, Grimaldi Forum.

The first AMI symposium, 'Design your patients' look with the NEW Signature approach by Allergan Aesthetics', will include:

    --  Two key signature looks from the AA Signature program - 'Lift Up' and
        'Distinct Definition'.
    --  The meeting will be co-chaired by leading experts Dr. Stefania Roberts
        (ANZ) and Dr. Andre Braz (Brazil), who'll facilitate discussions and
        live injections sessions with Dr. Sylwia Lipko-Godlewska (Poland), Dr.
        Marcel Vinicius (Brazil) and Dr. Lu Wang (China).

Day two will open with 'MD Codes(TM) and Allergan Aesthetics: a decade of excellence and a signature of success for the future'. Highlights will include:

    --  A deep dive into MD Codes(TM), its global presence and impact led by Dr.
        Maurício de Maio (Brazil), Dr. Nelson Chang (China), Dr. Iman Nurlin
        (Sweden), Dr. Sylwia Lipko-Godlewska (Poland) and Dr. Marcel Vinicius
        (Brazil).
    --  Expert speakers, live injection sessions and a fireside chat with Dr.
        Maurício de Maio who will explore the ongoing significance of
        hyaluronic acid as a key component in the modern multimodal treatment
        approach.

Beyond the AMI Symposia
Events will take place as follows:

    --  Science of Aging(TM) Symposium. 4:30 PM - 6:30 PM on Thursday, March 27
        in the Auric Room, Grimaldi Forum.
    --  Global Aesthetics Medical Affairs Symposium. 2:00 PM - 4:00 PM on
        Friday, March 28 in the Pinède1 room, Diaghilev level, Grimaldi Forum.

Exclusive Science of Aging(TM) Symposium: 'Bold scientific advances for a new age' brings together world-class experts to present the bold scientific advances within the field of aging. Dr. Stephanie Manson Brown, Vice President of R&D, Head of Clinical Development at Allergan Aesthetics, and Dr. Patricia Ogilvie (Germany) will open the event, followed by the discussion of key topics including skin longevity, genomics of aging, epigenetics of skin and mitraclock with Dr. Anne Chang from Stanford University (US), Dr. Howard Jacob from AbbVie (US) and Dr. Cristiana Banila of Mitra Bio (UK). The event will conclude with an engaging Q&A led by event chair Dr. Patricia Ogilvie.

Global Aesthetics Medical Affairs Symposium: 'Socially Transformative Aesthetic Medicine Impacting Emotion and Social Perception' will explore the multidimensional aspects of aesthetic medicine, and how aesthetic treatments not only enhance physical appearance but can also significantly impact emotional well-being and social perception. Chaired by Dr. Steven Dayan (US) alongside Dr. Sarah Boxley (Australia), Dr. Mitchell Brin (US), Prof. Dr. Dario Bertossi (Italy), and Dr. Ligia Colucci (Brazil), the expert panel will discuss the scientific data and provide clinical insights with transformative patient stories.

Meet the Experts
Meet the Experts sessions will be live from the Allergan Aesthetics booth, showcasing:

    --  AA Signature - Delivering a 360 approach to skin quality with Dr. Marion
        Runnebaum, Germany.
    --  Defining the lower face: The AA Signature Distinct Definition approach
        with Dr. Wenjin Wang, China.
    --  Celebrating 10 years of the MD Codes: Shaping your practice and
        treatment approach with Dr. Raafat Lakis, Dubai and Dr. Sheila Mulatti,
        Brazil.
    --  Optimising periorbital treatment to target aging effects: The Eye IMPACT
        study  with Dr. Sarah Boxley, Australia.

Across three days, the Allergan Aesthetics immersive booth (P3) will be a discovery hub for exploring the new AA Signature Program, where visitors can get hands-on with the portfolio, meet industry experts, experience the latest innovation in AA digital applications, and sign up to AMI Digital World.

E-Poster Sessions
Allergan Aesthetics' commitment to driving industry with advancing science and clinical data is demonstrated with the acceptance of 11 E-posters. The E-Posters will showcase the latest data and science supporting Allergan Aesthetics brand portfolio, looking specifically at the Skin Quality Lexicon and the multimodal approach of the Eye Impact Study.

Titles and named authors for the 11 posters to be showcased at AMWC:



     
              Presentation Topic                            
     
              Poster Title                                                     
     
              Authors



     HArmonyca Int'l Study - Interim ABS                        An International, Multicenter, Evaluator-blinded, Randomized, Parallel-       Andreas Nikolis, Nestor Demosthenous, Shannon Humphrey, Fernando
                                                                  Group, Controlled Study of the Safety and Effectiveness of HArmonyCa          Urdiales, Malka Salomon, Andrew Schumacher
                                                                  Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation





     HArmonyca MDR Final ABS AMWC Monaco                        Prospective, Open-label, Post Marketing Study of the Safety and
                                                                  Effectiveness of HArmonyCa Injectable Gel for Mid Face Soft Tissue
                                                                  Augmentation                                                                 Alessandro Gritti, Andrew Schumacher, Malka Salomon, Graeme Kerson





     SQ Attribute Definitions Part 2 ABS                        Establishing a Vocabulary for Skin Quality: Working Toward Consensus Skin     Shannon Humphrey, Derek Jones, Heather Woolery-Lloyd, Angeline Yong,
                                                                  Attribute Definitions From the Patient and Physician Perspective              Stephanie Manson Brown, Heather Lampel, Julie Garcia, Sherket Peterson


      MMP Psychosocial Impact HEOR -AMWC Monaco 2025 ABS         Psychosocial Impact of Masseter Muscle Prominence: Patient Perspectives       Catherine Foley, Julia Garcia, Martha Gauthier, Greg J Goodman, Shannon
                                                                  Across Multiple Regions                                                       Humphrey, Taro Kono, Elisabeth Lee, Grace Pan, Yan Wu




      Platysma Integrated Ph3 PRO 309/310 AMWC Monaco 2025 ABS   OnabotulinumtoxinA for the Treatment of Platysma Prominence: Patient-         Joely Kaufman, William P. Coleman, Amir Moradi, Steven Dayan, Patricia
                                                                  Reported Outcomes From 2 Phase 3 Multicenter, Randomized, Double-blind,       Ogilvie, Ava Shamban, Steve Yoelin, Warren Tong, Sandhya Shimoga
                                                                  Placebo-Controlled Studies




      Platysma Ph3 323 OL Extension AMWC Monaco 2025 ABS         Repeat Treatments of Moderate to Severe Platysma Prominence With              Terrence Keaney, Kenneth Beer, William Hanke, Ira Papel, Deanne Mraz,
                                                                  OnabotulinumtoxinA Has a Favorable Safety Profile in a Long-term, Phase 3,    Rodney Rohrich, Susan Weinkle, Steven Yoelin, Warren Tong, Rene
                                                                  Open-label Extension Study                                                    Hopfinger



     Platysma Ph3 323 OL PRO AMWC Monaco 2025 ABS               Patient-Reported Outcomes Across Repeat Treatments for Moderate to Severe     Shannon Humphrey, Sue Ellen Cox, Roy Geronemus, Terrence Keaney, Deanne
                                                                  Platysma Prominence in a Long-term, Phase 3, Open-label Extension Study       Mraz, Jennifer Nash, James Pehoushek, Rodney Rohrich, Rene Hopfinger,
                                                                                                                                                Sandhya Shimoga


      Natural Look Satisfaction Scale Botox AWMC Monaco 2025     Development of the Natural Look Satisfaction Scale for the Treatment of       Tanya Brandstetter, Annaliza Dominguez, Julia Garcia, Julie Whyte,
       ABS                                                        Upper Facial Lines With Neurotoxin                                            Martha Gauthier, Kian Karimi, Steve Yoelin, Carmen Kavali


      Vycross Botox Eye Impact -Upper /Midface Tx ABS            Improving Infraorbital Hollow Severity and Volume Through Mid- and Upper-     Gregory J Goodman, Samira Baharlou, Sarah Boxley, Pierre Cuvelier, Cara
                                                                  Face Treatment With Hyaluronic Acid (HA)-Fillers and OnabotulinumtoxinA       McDonald, Joan Vandeputte, Ivar Van Heijningen, Julia Garcia, Traci
                                                                                                                                                Baker, Smita Chawla, Carola de la Guardia, Frank Lin



     Vycross Botox Eye Impact PRO ABS                           Improvements in Age Perception and Psychological Well-Being After             Gregory J Goodman, Samira Baharlou, Sarah Boxley, Pierre Cuvelier, Cara
                                                                  Rejuvenation of the Eye Area Using Hyaluronic Acid-Based Fillers and          McDonald, Joan Vandeputte, Ivar Van Heijningen, Julia Garcia, Traci
                                                                  OnabotulinumtoxinA in the Mid- and Upper-Face                                 Baker, Smita Chawla, Carola de la Guardia, Frank Lin



     Vit C&E after Picosecond Laser Treatment                   Improvement in Skin Quality Using Vitamin C+E Complex Antioxidant Serum       Yang Qui, Caroline Aguilar, Johnny Chen, Kate Huang, Elizabeth T.
                                                                  After Picosecond Laser Treatment                                              Makino, Monica Zhu, Huangde Li

Notes to Editors

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas - immunology, oncology, neuroscience, and eye care - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.



     
                
                  Global Media:                     Investors:


     Michael Salzillo                          Liz Shea


     michael.salzillo1@allergan.com            liz.shea@abbvie.com




     
                U.S. Media:


     Adelle Infante


     Adelle.infante@allergan.com

*AA Signature, by Allergan Aesthetics, is a new program that Internationally in February 2025 and will be considered for roll out across International markets, as appropriate, over the next year.

View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-emphasizes-commitment-to-innovation-science-and-a-patient-centric-approach-at-amwc-2025-302409039.html

SOURCE AbbVie